Albert S, Brason II FW, Sanford CK, Dasgupta N, Graham J, Lovette B. Project lazarus: community-based overdose prevention in rural north Carolina. Pain Medicine 2011;12 Suppl 2:S77-85.
Bailey AM, Wermeling DP. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings. Ann Pharmacother 2014;48(5):601-6.
Barton ED, Ramos J, Colwell C, Benson J, Baily J, Dunn W. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care 2002;6(1):54-8.
Behar E, Santos GM, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend 2015;148:209-12.
Beletsky L. The benefits and potential drawbacks in the approval of EVZIO for lay reversal of opioid overdose. Am J Prev Med 2015;48(3):357-9.
Beletsky L, Ruthazer R, Macalino GE, Rich JD, Tan L, Burris S. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health 2007;84(1):126-36.
Bigg D, Maxwell S. Enabling people to stay alive: an effective opiate overdose prevention program. In: Fourth National Harm Reduction Conference. Seattle, WA; 2002.
Boyd JJ, Kuisma MJ, Alaspaa AO, Vuori E, Repo JV, Randell TT. Recurrent opioid toxicity after pre-hospital care of presumed heroin overdose patients. Acta Anaesthesiol Scand 2006;50(10):1266-70.
Buajordet I, Naess AC, Jacobsen D, Brors O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med 2004;11(1):19-23.
Burris S, L. B, Castagna C, Coyle C, Crowe C, McLaughlin J. Stopping an Invisible Epidemic: Legal Issues in the Provision of Naloxone to Prevent Opioid Overdose. Drexel Law Review 2009;1(2).
Bouillon T, Bruhn J, Roepcke H, Hoeft A. Opioid-induced respiratory depression is associated with increased tidal volume variability. Eur J Anaesthesiol 2003;20(2):127-33.
Coffin PO, Sullivan SD. Cost- effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013;158(1):1-9.
Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61(6):101-5.
Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med 1994;12 (6):650-60.
Chen L, Hedegaard H, Warner M. Drug- poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011. NCHS Data Brief 2014(166):1-8.
Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014;8(3):153-63.
Coffin PO, Fuller C, Vadnai L, Blaney S, Galea S, Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J Urban Health 2003;80(2):288-90.
Dasgupta N, Creppage K, Austin A, Ringwalt C, Sanford C, Proescholdbell SK. Observed transition from opioid analgesic deaths toward heroin. Drug Alcohol Depend 2014;145:238-41.
Davis CS. Legal Interventions to Reduce Overdose Mortality: Naloxone access and overdose good samaritan laws: Network for Public Health Law; 2015.
Davis CS, Ruiz S, Glynn P, Picariello G, Walley AY. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am J Public Health 2014;104(8):e7- 9.
Davis CS, Southwell JK, Niehaus VR, Walley AY, Dailey MW. Emergency Medical Services Naloxone Access: A National Systematic Legal Review. Acad Emerg Med 2014;21(10):1173-1177.
Davis C, Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics 2013;41 Suppl 1:33-6.
Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health 2014;14:297.
Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009;99(5):788-91.
Enteen L, Bauer J, McLean R, Wheeler E, Huriaux E, Kral AH, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010;87(6):931-41.
Food and Drug Administration. FDA approves new hand-held auto-injector to reverse opioid overdose. In: First naloxone treatment specifically designed to be given by family members or caregivers. Washington, D.C.; 2014.
Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav 2006;31(5):907-12.
Goodman J. Naloxone, a drug to stop heroin deaths, is more costly, the police say. New York Times 2014 December 1, 2014.
Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008;103(6):979-89.
Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we know, and don't know, about the impact of state policy and systems- level interventions on prescription drug overdose. Drug Alcohol Depend 2014;145C:34- 47.
Hedegaard H, Chen LH, Warner M. Drug- poisoning Deaths Involving Heroin: United States, 2000-2013. NCHS Data Brief 2015 (190):1-8.
Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend 2013;132(1-2):95-100.
Kelly AM, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust 2005;182 (1):24-7.
L C, H H, Warner M. QuickStats: Rates of deaths from drug poisoning and drug poisoning involving opioid analgesics—United States, 1999–2013. Morbidity and Mortality Weekly Report 2015;64(01):32
Lewanowitsch T, Irvine RJ. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal. Eur J Pharmacol 2002;445(1-2):61-7.
Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis 2006;25(3):89-96.
Michiels C. Physiological and pathological responses to hypoxia. Am J Pathol 2004;164(6):1875-82.
Modarai F, Mack K, Hicks P, Benoit S, Park S, Jones C, et al. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend 2013;132(1-2):81-6.
Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363(21):1981-5.
Osterwalder JJ. Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol 1996;34(4):409-16.
Pattinson KT. Opioids and the control of respiration. Br J Anaesth 2008;100(6):747-58.
Peavy KM, Banta-Green CJ, Kingston S, Hanrahan M, Merrill JO, Coffin PO. "Hooked on" prescription-type opiates prior to using heroin: results from a survey of syringe exchange clients. J Psychoactive Drugs 2012;44(3):259-65.
Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, et al. Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse 2008;43(7):858-70.
Pollini RA, Banta-Green CJ, Cuevas-Mota J, Metzner M, Teshale E, Garfein RS. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst Abuse Rehabil 2011;2(1):173- 180.
Rossen LM, Khan D, Warner M. Trends and geographic patterns in drug-poisoning death rates in the u.s., 1999-2009. Am J Prev Med 2013;45(6):e19-25.
Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO. Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program. Addiction 2015.
Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D, et al. Increases in heroin overdose deaths - 28 States, 2010 to 2012. MMWR Morb Mortal Wkly Rep 2014;63(39):849-54.
Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 2005;82(2):303-11.
Sherman SG, Gann DS, Scott G, Carlberg S, Bigg D, Heimer R. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct J 2008;5:
Simini B. Balogna-Naloxone supplied to Italian heroin addicts. Lancet 1998;352(9132):967.
Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. Bmj 1996;312(7044):1435- 6.Warner M, Chen LH, Makuc DM, Anderson RN, Minino AM. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief 2011(81):1-8.
Strang J, Powis B, Best D, Vingoe L, Griffiths P, Taylor C, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction 1999;94 (2):199-204.
Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. Addiction 2005;100(3):397-404.
Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med 2003;10(8):893-6.
Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley JH, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy 2010;21(3):186-93.
Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013;346:f174.
Wampler DA, Molina DK, McManus J, Laws P, Manifold CA. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care 2011;15(3):320-4.
Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf 2015;6(1):20-31.
Wheeler E, Jones ST, Gilbert MK, Davidson PJ. Opioid overdose prevention programs providing naloxone to laypersons – United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64(23):631-5.
White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999;94(7):961-72.
Yokell MA, Green TC, Bowman S, McKenzie M, Rich JD. Opioid overdose prevention and naloxone distribution in Rhode Island. Med Health R I 2011;94(8):240-2.
Zaller ND, Yokell MA, Green TC, Gaggin J, Case P. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse 2013;48(8):590-9.